Generative AI Empowers Digital Psychotherapy: "Wangli Technology" Secures Tens of Millions in Series B+ Round Financing | Exclusive Report by 36Kr

Text | Hu Xiangyun

Editor | Hai Ruojing

36Kr learned that the digital mental health diagnosis and treatment platform "Wangli Technology" has completed a tens of millions of yuan Series B+ financing round. This round of financing was exclusively invested by Yuanyi Capital, and the raised funds will be mainly used for product R & D. In addition, Wangli Technology has also launched a new round of financing, with Index Capital serving as the financial advisor.

Wangli Technology focuses on the mental health field. Its self - built database in this field has accumulated 300,000 real - world patient data. Moreover, Wangli Technology has published more than a dozen papers in international authoritative journals in psychiatry and has undertaken multiple national and provincial - ministerial level scientific research projects. In terms of application, the company can provide a complete solution of "professional equipment + APP + professional staff" for customers in different industries. Its one - stop psychological service solution has covered more than 100 cities in 16 provinces across the country.

Li Dai, the founder and CEO of Wangli Technology, introduced that based on the continuous accumulation of a large amount of high - quality multi - modal data and the professionally fine - tuned corpora of clinical experts, physicians, psychotherapists, and counselors from multiple disciplines such as psychiatry and neurology, Wangli Technology has created a full - node knowledge graph and the WonderLab large model that integrates multi - dimensional psychological therapies and cognitive training paradigms such as CBT/ACT/PPT/CBM. With this as the professional knowledge foundation, Wangli Technology has deeply integrated optimization theories such as reinforcement learning (RL) and just - in - time adaptive intervention (JITAI) to construct a unique treatment optimization algorithm.

Specifically, through the "macro - meso - micro" three - level recommendation engine, this algorithm system can perceive the user's state changes in real - time and adjust the intervention path, accurately match the current optimal intervention task from a large pool of intervention parameters and content, and achieve precise intervention tailored to each individual.

"From the patients' intuitive experience, this is helpful in improving treatment efficacy and compliance. For example, some patients have accumulated more than 100,000 words of dialogue data in our software products," said Li Dai.

In December 2025, Wangli Technology's anti - depression product "Depression Symptom Auxiliary Treatment Software" (trade name: Wangli Nuanyang WL - iCBT) based on digital psychotherapy (iCBT) was approved for the Class III medical device registration certificate, becoming the first digital medical product in China to obtain a Class III certificate in the field of anti - depression and mental/neurological disease treatment.

It is reported that "Wangli Nuanyang" is developed based on mobile Internet technology, combined with big data and personalized algorithms. It includes functions such as evidence - based multi - modal cognitive behavioral therapy and thinking improvement training. It can dynamically adjust the training and treatment levels according to the patients' individualized treatment conditions, is less restricted by location and time, and can better meet the patients' treatment needs.

Based on the characteristics of mental/neurological diseases and the requirements of current regulatory documents, Class III medical devices are a necessity for the treatment of most mental health diseases. Therefore, before going on the market, strict large - sample clinical trials are required to verify the efficacy.

It is understood that the registration clinical trial of "Wangli Nuanyang" was led by the National Center for Mental Health and other institutions, with a total of 11 hospitals across the country participating. It evaluated the main clinical indicators such as anti - depression efficacy, safety, and compliance, as well as secondary treatment indicators such as anxiety and cognition.

Li Dai introduced that one of the major difficulties in this process is how to accurately provide "real - world" trial data to ensure that the research results have clear reference and guidance for the subsequent actual clinical application of the product. For example, if the enrolled patients have other clinically diagnosed diseases or have taken medications in the short term, it will affect their physiological signal data, leading to deviations in the model training process. In response, Wangli Technology conducts a large number of strict tests when recruiting patients, and requires the consistent evaluation of two doctors to confirm enrollment.

Currently, "Wangli Nuanyang" has been recommended as a Class 1A treatment method in the 2025 edition of the "Chinese Guidelines for the Prevention and Treatment of Depressive Disorders" and has a dedicated payment item in hospitals. This also means that its subsequent commercialization path is becoming clearer.

Li Dai said that although the product has been certified for a relatively short time, due to its relatively innovative psychological treatment concepts and methods and convenient form, "patients' acceptance and hospitals' enthusiasm for introduction are relatively high" at present.

Image source: Wangli Technology